Table 1.
Baseline characteristics of inpatients with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection according to the variant responsible for the infection
| Variables | B.1.616 n = 39 |
Undetermined variant n = 43 |
VOC n = 32 |
p |
|---|---|---|---|---|
| Age, year (IQR) | 81 (73–88) | 80 (68–87) | 73 (67–82) | 0.022 |
| Male, n (%) | 21 (54%) | 24 (56%) | 15 (47%) | 0.732 |
| Body mass index, kg/m2 (IQR) | 25 (22–29) | 26 (23–28) | 31 (27–33) | 0.012 |
| Comorbidities | ||||
| No comorbidity, n (%) | 6 (18%) | 9 (19%) | 4 (13%) | 0.812 |
| Cardiovascular disease, n (%) | 22 (56%) | 20 (47%) | 11 (34%) | 0.560 |
| Chronic respiratory disease, n (%) | 8 (21%) | 9 (21%) | 5 (16%) | 0.824 |
| Chronic kidney failure, n (%) | 12 (31%) | 7 (16%) | 5 (16%) | 0.185 |
| Cirrhosis, n (%) | 4 (10%) | 4 (9%) | 1 (3%) | 0.518 |
| Neurological disease, n (%) | 11 (28%) | 5 (12%) | 10 (31%) | 0.082 |
| Cancer, n (%) | 12 (31%) | 11 (26%) | 10 (31%) | 0.826 |
| Immunodepression, n (%) | 4 (10%) | 1 (2%) | 5 (16%) | 0.120 |
| Diabetes, n (%) | 9 (23%) | 11 (26%) | 6 (19%) | 0.783 |
| Hypertension, n (%) | 22 (56%) | 19 (44%) | 22 (69%) | 0.105 |
| Healthcare-associated COVID-19, n (%) | 37 (95%) | 17 (40%) | 10 (31%) | <0.001 |
| Clinical findings | ||||
| Fever, n (%) | 24 (61%) | 27 (63%) | 21 (66%) | 0.397 |
| Temperature, °C | 38.2 (37.0–38.8) | 38 (37.7–38.5) | 37.8 (37.0–38.8) | 0.732 |
| Dyspnoea, n (%) | 26 (67%) | 27 (63%) | 14 (44%) | 0.118 |
| Oxygen saturation, % | 91 (90–94) | 93 (92–96) | 94 (89 - 96) | 0.171 |
| Cough, n (%) | 14 (36%) | 15 (35%) | 14 (44%) | 0.705 |
| Headache, n (%) | 2 (5%) | 3 (7%) | 1 (3%) | 0.876 |
| Delirium, n (%) | 6 (15%) | 5 (12%) | 2 (6%) | 0.534 |
| Fatigue, n (%) | 9 (23%) | 14 (33%) | 12 (38%) | 0.400 |
| Anosmia, n (%) | 1 (3%) | 2 (5%) | 0 | 0.777 |
| Digestive symptoms, n (%) | 4 (10%) | 5 (12%) | 1 (3%) | 0.417 |
| Rhinorrhoea, n (%) | 0 | 1 (2%) | 2 (6%) | 0.279 |
| No symptoms – n (%) | 0 | 4 (9%) | 4 (12%) | 0.053 |
| Biological findings | ||||
| Neutrophils, x 109/L | 5140 (3245–7775) | 4050 (3150–8110) | 4130 (1440–6700) | 0.166 |
| Lymphocytes, x 109/L | 650 (425–1055) | 730 (580–1050) | 780 (610–1060) | 0.526 |
| Serum C-reactive protein, mg/mL | 79 (43–122) | 51 (16–142) | 49 (12–92) | 0.163 |
| D-dimers, μg/L | 1330 (589–1714) | 722 (521–1609) | 1528 (930–1942) | 0.476 |
| Thorax computed tomography (CT) | ||||
| No CT scan, n | 9 (23%) | 18 (42%) | 12 (37%) | |
| <25%, n (%)a | 9 (23%) | 9 (21%) | 5 (16%) | 0.953 |
| 25–50%, n (%)a | 12 (35%) | 11 (26%) | 9 (28%) | |
| 50-75%, n (%)a | 8 (21%) | 5 (12%) | 5 (16%) | |
| >75%, n (%)a | 1 (3%) | 0 | 1 (3%) | |
| Pulmonary embolism, n (%) | 3 (8%) | 1 (2%) | 2 (6%) | 0.583 |
| Time from symptoms onset to first RT-PCR test, days (IQR) | 0 (0–2) | 0 (0–5) | 3 (1–5) | 0.004 |
| Time from symptoms onset to first SARS-CoV-2 detection, days (IQR) | 3 (2–9) | 4 (1–7) | 1 (0–4) | 0.059 |
| First RT-PCR positive for SARS-CoV-2, n (%) | 6 (15%) | 10 (23%) | 31 (97%) | <0.001 |
| At least one RT-PCR positive for SARS-CoV-2, n (%) | 26 (67%) | 24 (56%) | 32 (100%) | <0.001 |
| Number of RT-PCR tests per patient | <0.001 | |||
| 1 | 6 (15%) | 13 (30%) | 31 (97%) | |
| 2 | 12 (31%) | 17 (40%) | 1 (3%) | |
| >3 | 21 (54%) | 13 (30%) | 0 | |
| Site of sample (first positive RT-PCR only), n | <0.001 | |||
| Endotracheal aspirate | 0 | 2 (5%) | 0 | |
| Expectoration | 2 (5%) | 0 | 0 | |
| Bronchoalveolar lavage | 5 (13%) | 0 | 0 | |
| Nasopharyngeal swab | 13 (33%) | 22 (451%) | 32 (100%) | |
| Stool | 0 | 1 (2%) | 0 | |
| CT value (positive RT-PCR only) | ||||
| Nasopharyngeal sample | 29 (27–36) | 35 (30–40) | 19 (14–22) | <0.001 |
| Lower respiratory tract sample | 33 (33–35) | 45 (45–45) | 26 | 0.035 |
VOC, variant of concern.
a
Proportion of lung involved.